136 related articles for article (PubMed ID: 12963845)
1. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.
Wingate H; Bedrosian I; Akli S; Keyomarsi K
Cell Cycle; 2003; 2(5):461-6. PubMed ID: 12963845
[TBL] [Abstract][Full Text] [Related]
2. Lower molecular weight forms of cyclin E--super activators of the cell cycle?
Stighall M; Berglund P; Landberg G
Cell Cycle; 2003; 2(5):458-60. PubMed ID: 12963844
[No Abstract] [Full Text] [Related]
3. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Akli S; Zheng PJ; Multani AS; Wingate HF; Pathak S; Zhang N; Tucker SL; Chang S; Keyomarsi K
Cancer Res; 2004 May; 64(9):3198-208. PubMed ID: 15126360
[TBL] [Abstract][Full Text] [Related]
4. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.
Harwell RM; Mull BB; Porter DC; Keyomarsi K
J Biol Chem; 2004 Mar; 279(13):12695-705. PubMed ID: 14701826
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms.
Porter DC; Zhang N; Danes C; McGahren MJ; Harwell RM; Faruki S; Keyomarsi K
Mol Cell Biol; 2001 Sep; 21(18):6254-69. PubMed ID: 11509668
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.
Wingate H; Puskas A; Duong M; Bui T; Richardson D; Liu Y; Tucker SL; Van Pelt C; Meijer L; Hunt K; Keyomarsi K
Cell Cycle; 2009 Apr; 8(7):1062-8. PubMed ID: 19305161
[TBL] [Abstract][Full Text] [Related]
7. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Wingate H; Zhang N; McGarhen MJ; Bedrosian I; Harper JW; Keyomarsi K
J Biol Chem; 2005 Apr; 280(15):15148-57. PubMed ID: 15708847
[TBL] [Abstract][Full Text] [Related]
8. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
9. Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?
Rath SL; Senapati S
Biochemistry; 2014 Jul; 53(28):4612-24. PubMed ID: 24947816
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma.
Gladden AB; Diehl JA
Cancer Cell; 2003 Sep; 4(3):160-2. PubMed ID: 14522248
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.
Bagheri-Yarmand R; Nanos-Webb A; Biernacka A; Bui T; Keyomarsi K
Cancer Res; 2010 Jun; 70(12):5085-95. PubMed ID: 20530684
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Cyclin E and its Low Molecular Weight Isoforms Cooperate with Loss of p53 in Promoting Oncogenic Properties of MCF-7 Breast Cancer Cells.
Montazeri H; Bouzari S; Azadmanesh K; Ostad SN; Ghahremani MH
Asian Pac J Cancer Prev; 2015; 16(17):7575-82. PubMed ID: 26625764
[TBL] [Abstract][Full Text] [Related]
13. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo.
Bales E; Mills L; Milam N; McGahren-Murray M; Bandyopadhyay D; Chen D; Reed JA; Timchenko N; van den Oord JJ; Bar-Eli M; Keyomarsi K; Medrano EE
Cancer Res; 2005 Feb; 65(3):692-7. PubMed ID: 15705861
[TBL] [Abstract][Full Text] [Related]
14. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.
Duong MT; Akli S; Macalou S; Biernacka A; Debeb BG; Yi M; Hunt KK; Keyomarsi K
Cancer Res; 2013 Sep; 73(17):5556-68. PubMed ID: 23955388
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclin D1 overexpression on G1 progression-related events.
Imoto M; Doki Y; Jiang W; Han EK; Weinstein IB
Exp Cell Res; 1997 Oct; 236(1):173-80. PubMed ID: 9344597
[TBL] [Abstract][Full Text] [Related]
17. Novel splice variants of cyclin E with altered substrate specificity.
Porter DC; Keyomarsi K
Nucleic Acids Res; 2000 Dec; 28(23):E101. PubMed ID: 11095697
[TBL] [Abstract][Full Text] [Related]
18. The cyclin E/Cdk2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells.
Ye X; Wei Y; Nalepa G; Harper JW
Mol Cell Biol; 2003 Dec; 23(23):8586-600. PubMed ID: 14612403
[TBL] [Abstract][Full Text] [Related]
19. Processing of cyclin E differs between normal and tumor breast cells.
Harwell RM; Porter DC; Danes C; Keyomarsi K
Cancer Res; 2000 Jan; 60(2):481-9. PubMed ID: 10667604
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle.
Lauper N; Beck AR; Cariou S; Richman L; Hofmann K; Reith W; Slingerland JM; Amati B
Oncogene; 1998 Nov; 17(20):2637-43. PubMed ID: 9840927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
